INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2015

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following:

	December 31,
	2015			2014
Intangible assets:
Finite-lived intangible assets	$	129,572		$	123,365
Indefinite-lived intangible assets		607,548			74,430
Gross intangible assets:		737,120			197,795
Less: Accumulated amortization		(53,124	)		(41,217	)
Net carrying value	$	683,996		$	156,578

Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets

The following table summarizes the net-book-value and estimated remaining life of the Company’s finite-lived intangible assets at December 31, 2015:

	Net Balance at December 31, 2015		Average Remaining Life
Repurchased royalty rights	$	53,438	7.9 years
Acquired intellectual property		19,652	8.6 years
License payments for marketing approvals		2,380	5.7 years
SRCC in-place and above market tenant leases		978	Remaining lease terms
Total	$	76,448

Schedule of Future Amortization Expense of Finite-Lived Intangible Assets

As of December 31, 2015, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:

Fiscal Year	Amount
2016	$	11,371
2017		10,904
2018		10,874
2019		10,605
2020		8,188
Thereafter		24,506
	$	76,448

Schedule of Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets consisted of the following:

	December 31,
	2015		2014
In-Process Research and Development:
Talazoparib	$	—	$	35,150
Kyndrisa		533,064		—
Other exons		41,044		—
Reveglucosidase alfa		25,010		25,010
Other acquired pre-clinical compounds		8,430		14,270
Net carrying value	$	607,548	$	74,430